Oral Delivery of Gambogenic Acid by Functional Polydopamine Nanoparticles for Targeted Tumor Therapy
journal contributionposted on 14.02.2021, 15:13 by Beilei Wang, Tengteng Yuan, Liqiong Zha, Yuanxu Liu, Weidong Chen, Caiyun Zhang, Youmei Bao, Qiannian Dong
To enhance the water solubility, oral bioavailability, and tumor targeting of gambogenic acid (GNA), polydopamine nanoparticles (PDA NPs) were prepared to encapsulate and stabilize GNA surface modified by folic acid (FA) and then coated with sodium alginate (GNA@PDA-FA SA NPs) to achieve an antitumor effect by oral administration. GNA@PDA-FA SA NPs exhibited in vitro pH-sensitive release behavior. In vitro cell studies manifested that GNA@PDA-FA NPs had higher cytotoxicity to 4T1 cells compared with raw GNA (IC50 = 2.58 μM vs 7.57 μM). After being modified with FA, GNA@PDA-FA NPs were taken up easily by 4T1 cells. In vivo studies demonstrated that the area under the curve (AUC0→∞) of the plasma drug concentration–time of GNA@PDA-FA SA NPs was 2.97-fold higher than that of raw GNA, along with improving drug distribution in the liver, lung, and kidney tissues. In vivo anti-tumor experiments, GNA@PDA-FA SA NPs significantly inhibited the growth of breast tumors in the 4T1 xenograft breast cancer model via oral administration without obvious toxicity on major organs. Our studies indicated that the GNA@PDA-FA SA NPs modified with FA and coated with SA were a promising drug delivery system for targeting tumor therapy via oral administration.
Read the peer-reviewed publication
cell studiesGNA surfacebreast tumorspH-sensitive release behaviordrug distributiondrug delivery systemwater solubilityantitumor effectvivo studies2.58 μ M vs 7.57 μ Msodium alginategambogenic acidTargeted Tumor Therapyfolic acidkidney tissuesFA4 T 1 cellsFunctional Polydopamine Nanoparticles4 T 1 xenograft breast cancer modelOral DeliveryAUCPDA NPstumor therapyIC 50vivo anti-tumor experimentsSA